JP Morgan Chase’s Travere Therapeutics TVTX Stock Holding History

JP Morgan Chase’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.7K	Buy	+200	New	+$8.87K	﹤0.01%	6878
2026 Q1	–	Sell	-28,600	Closed	-$1.09M	–	7907
2025 Q4	$1.09M	Buy	+28,600	New	+$930K	﹤0.01%	4544
2025 Q3	–	Sell	-1,500	Closed	-$22.2K	–	7733
2025 Q2	$22.2K	Buy	+1,500	New	+$24.9K	﹤0.01%	6146
2025 Q1	–	Sell	-5,900	Closed	-$103K	–	7739
2024 Q4	$103K	Buy	+5,900	New	+$104K	﹤0.01%	5750
2024 Q2	–	Sell	-70,000	Closed	-$540K	–	7752
2024 Q1	$540K	Hold	70,000	–	–	﹤0.01%	4741
2023 Q4	$629K	Buy	+70,000	New	+$510K	﹤0.01%	4647

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's TVTX Position: Q2 2026 in Review

JP Morgan Chase reduced its Travere Therapeutics (TVTX) stake by 7.2% in Q2 2026, selling an estimated $916K and leaving 267,889 shares worth $15.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

JP Morgan Chase first reported a position in TVTX in Q4 2015 and has held it in 42 quarters since. The position peaked at $35.2M in Q4 2021. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

JP Morgan Chase held 267,889 shares of Travere Therapeutics worth $15.9M as of Q2 2026.
JP Morgan Chase sold 20,662 Travere Therapeutics shares in Q2 2026, an estimated $916K.
Travere Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2407 holding.
JP Morgan Chase first reported a position in Travere Therapeutics in Q4 2015 and has held it in 42 quarters since.
JP Morgan Chase's Travere Therapeutics position peaked at $35.2M in Q4 2021.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.